Lirilumab

DRUG11 trials

Sponsors

Bristol-Myers Squibb, M.D. Anderson Cancer Center, Gustave Roussy, Cancer Campus, Grand Paris, Dana-Farber Cancer Institute, Incyte Corporation

Conditions

Acute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdvanced CancerCANCER, NOSCANCER,NOSChronic Lymphocytic LeukemiaHodgkin LymphomaLeukemia

Phase 1

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

CompletedNCT01592370

Bristol-Myers SquibbHodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma

Start: 2012-08-02End: 2024-07-09Updated: 2025-10-22

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CompletedNCT01714739

Bristol-Myers SquibbCANCER,NOS

Start: 2012-10-07End: 2019-12-13Updated: 2023-02-02

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

CompletedNCT01750580

Bristol-Myers SquibbCANCER, NOS

Start: 2012-12-31End: 2015-04-30Updated: 2015-07-22

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

CompletedNCT02252263

Bristol-Myers SquibbMultiple Myeloma

Start: 2014-12-09End: 2017-10-10Updated: 2017-11-01

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

RecruitingNCT02813135

Gustave Roussy, Cancer Campus, Grand ParisPediatric Cancer

Start: 2016-08-03End: 2031-02-01Target: 472Updated: 2026-01-16

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

CompletedNCT03203876

Bristol-Myers SquibbAdvanced Cancer

Start: 2017-07-14End: 2020-08-06Updated: 2022-03-10

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

TerminatedNCT03347123

Incyte CorporationSolid Tumors

Start: 2018-03-21End: 2021-01-29Updated: 2022-02-28

Phase 2

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

TerminatedNCT02399917

M.D. Anderson Cancer CenterAcute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia +1

Start: 2015-04-20End: 2018-07-12Updated: 2019-09-24

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

CompletedNCT02481297

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia, Leukemia, Lymphocytic Leukemia

Start: 2015-06-23End: 2019-08-15Updated: 2020-05-28

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

TerminatedNCT02599649

M.D. Anderson Cancer CenterLeukemia

Start: 2016-03-21End: 2019-01-30Updated: 2020-01-14

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Active, not recruitingNCT03341936

Dana-Farber Cancer InstituteSquamous Cell Carcinoma of the Head and Neck

Start: 2018-03-15End: 2026-07-06Updated: 2025-06-18

Related Papers

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial

Frontiers in Hematology2023-09-122 citations

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

Cancer Discovery2022-03-16143 citations

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

Journal of Clinical Oncology2021-05-2017 citations

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

Cancers2021-05-1820 citations

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

BMC Cancer2020-06-0535 citations

Relevant Biomarkers for the Treatment of Hematological Malignancies

Oncology Times2019-08-28

AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan.

Journal of Clinical Oncology2019-05-208 citations

Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.

Journal of Clinical Oncology2019-05-205 citations

Novel Use of Pembrolizumab & Lenalidomide in Mycosis Fungoides

Oncology Times2019-03-14

Analysis of Immune-Related Adverse Reactions in Patients with Classical Hodgkin Lymphoma (cHL) on Programmed Death-1 (PD-1) Inhibitor Therapy

Blood2018-11-294 citations

EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM

Neuro-Oncology2018-06-01

Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML

Blood2017-12-075 citations

Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study

Cancer Research2017-07-019 citations

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

Journal of Clinical Oncology2017-05-209 citations

Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study.

Journal of Clinical Oncology2017-05-202 citations

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Blood2016-12-02134 citations

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Blood2016-12-0226 citations

Abstract 2044: Pharmacokinetics (PK) of nivolumab in patients with relapsed or refractory lymphoid malignancies

Cancer Research2016-07-151 citations

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.

Journal of Clinical Oncology2016-05-2015 citations

4 more papers not shown